A case series of lengthy progression-free survival with pemetrexed-containing therapy in metastatic non-small-cell lung cancer patients harboring ros1 gene rearrangements

Jonathan Riess, Sukhmani K. Padda, Charles D. Bangs, Millie Das, Joel W. Neal, Adour R. Adrouny, Athena Cherry, Heather A. Wakelee

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Tumors with c-ros oncogene 1 (ROS1) translocations are a newly discovered molecular subset of non esmall-cell lung cancer (NSCLC). Like anaplastic lymphoma receptor tyrosine kinase (ALK)-rearranged NSCLC, early phase clinical trials show a high response rate to crizotinib in these patients. Some retrospective studies suggest patients with ALKP tumorshave a longer progression-free survival (PFS) to pemetrexed compared with other chemotherapeutics- though this is controversial. Little is known about whether patients with ROS1-rearranged tumors preferentially respond to specific chemotherapy drugs. This small, retrospective case series suggests that some NSCLC patients whose tumors harbor the ROS1 gene rearrangements might have a lengthy PFS using pemetrexed-containing therapy. In clinical practice, oncologists might want to consider pemetrexed-containing regimens when chemotherapy is indicated.

Original languageEnglish (US)
Pages (from-to)592-595
Number of pages4
JournalClinical Lung Cancer
Volume14
Issue number5
DOIs
StatePublished - Sep 2013
Externally publishedYes

Fingerprint

Pemetrexed
Gene Rearrangement
Non-Small Cell Lung Carcinoma
Disease-Free Survival
Lung Neoplasms
Drug Therapy
Neoplasms
Therapeutics
Oncogenes
Retrospective Studies
Clinical Trials
Pharmaceutical Preparations

Keywords

  • Chemotherapy
  • Molecular subtypes
  • NSCLC
  • Pemetrexed
  • ROS1

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this

A case series of lengthy progression-free survival with pemetrexed-containing therapy in metastatic non-small-cell lung cancer patients harboring ros1 gene rearrangements. / Riess, Jonathan; Padda, Sukhmani K.; Bangs, Charles D.; Das, Millie; Neal, Joel W.; Adrouny, Adour R.; Cherry, Athena; Wakelee, Heather A.

In: Clinical Lung Cancer, Vol. 14, No. 5, 09.2013, p. 592-595.

Research output: Contribution to journalArticle

Riess, Jonathan ; Padda, Sukhmani K. ; Bangs, Charles D. ; Das, Millie ; Neal, Joel W. ; Adrouny, Adour R. ; Cherry, Athena ; Wakelee, Heather A. / A case series of lengthy progression-free survival with pemetrexed-containing therapy in metastatic non-small-cell lung cancer patients harboring ros1 gene rearrangements. In: Clinical Lung Cancer. 2013 ; Vol. 14, No. 5. pp. 592-595.
@article{f438409d1bdc4a1ab4261105d4da2a24,
title = "A case series of lengthy progression-free survival with pemetrexed-containing therapy in metastatic non-small-cell lung cancer patients harboring ros1 gene rearrangements",
abstract = "Tumors with c-ros oncogene 1 (ROS1) translocations are a newly discovered molecular subset of non esmall-cell lung cancer (NSCLC). Like anaplastic lymphoma receptor tyrosine kinase (ALK)-rearranged NSCLC, early phase clinical trials show a high response rate to crizotinib in these patients. Some retrospective studies suggest patients with ALKP tumorshave a longer progression-free survival (PFS) to pemetrexed compared with other chemotherapeutics- though this is controversial. Little is known about whether patients with ROS1-rearranged tumors preferentially respond to specific chemotherapy drugs. This small, retrospective case series suggests that some NSCLC patients whose tumors harbor the ROS1 gene rearrangements might have a lengthy PFS using pemetrexed-containing therapy. In clinical practice, oncologists might want to consider pemetrexed-containing regimens when chemotherapy is indicated.",
keywords = "Chemotherapy, Molecular subtypes, NSCLC, Pemetrexed, ROS1",
author = "Jonathan Riess and Padda, {Sukhmani K.} and Bangs, {Charles D.} and Millie Das and Neal, {Joel W.} and Adrouny, {Adour R.} and Athena Cherry and Wakelee, {Heather A.}",
year = "2013",
month = "9",
doi = "10.1016/j.cllc.2013.04.008",
language = "English (US)",
volume = "14",
pages = "592--595",
journal = "Clinical Lung Cancer",
issn = "1525-7304",
publisher = "Elsevier",
number = "5",

}

TY - JOUR

T1 - A case series of lengthy progression-free survival with pemetrexed-containing therapy in metastatic non-small-cell lung cancer patients harboring ros1 gene rearrangements

AU - Riess, Jonathan

AU - Padda, Sukhmani K.

AU - Bangs, Charles D.

AU - Das, Millie

AU - Neal, Joel W.

AU - Adrouny, Adour R.

AU - Cherry, Athena

AU - Wakelee, Heather A.

PY - 2013/9

Y1 - 2013/9

N2 - Tumors with c-ros oncogene 1 (ROS1) translocations are a newly discovered molecular subset of non esmall-cell lung cancer (NSCLC). Like anaplastic lymphoma receptor tyrosine kinase (ALK)-rearranged NSCLC, early phase clinical trials show a high response rate to crizotinib in these patients. Some retrospective studies suggest patients with ALKP tumorshave a longer progression-free survival (PFS) to pemetrexed compared with other chemotherapeutics- though this is controversial. Little is known about whether patients with ROS1-rearranged tumors preferentially respond to specific chemotherapy drugs. This small, retrospective case series suggests that some NSCLC patients whose tumors harbor the ROS1 gene rearrangements might have a lengthy PFS using pemetrexed-containing therapy. In clinical practice, oncologists might want to consider pemetrexed-containing regimens when chemotherapy is indicated.

AB - Tumors with c-ros oncogene 1 (ROS1) translocations are a newly discovered molecular subset of non esmall-cell lung cancer (NSCLC). Like anaplastic lymphoma receptor tyrosine kinase (ALK)-rearranged NSCLC, early phase clinical trials show a high response rate to crizotinib in these patients. Some retrospective studies suggest patients with ALKP tumorshave a longer progression-free survival (PFS) to pemetrexed compared with other chemotherapeutics- though this is controversial. Little is known about whether patients with ROS1-rearranged tumors preferentially respond to specific chemotherapy drugs. This small, retrospective case series suggests that some NSCLC patients whose tumors harbor the ROS1 gene rearrangements might have a lengthy PFS using pemetrexed-containing therapy. In clinical practice, oncologists might want to consider pemetrexed-containing regimens when chemotherapy is indicated.

KW - Chemotherapy

KW - Molecular subtypes

KW - NSCLC

KW - Pemetrexed

KW - ROS1

UR - http://www.scopus.com/inward/record.url?scp=84883816641&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883816641&partnerID=8YFLogxK

U2 - 10.1016/j.cllc.2013.04.008

DO - 10.1016/j.cllc.2013.04.008

M3 - Article

C2 - 23810364

AN - SCOPUS:84883816641

VL - 14

SP - 592

EP - 595

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

SN - 1525-7304

IS - 5

ER -